Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Down 17.5% in December

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) was the target of a significant decrease in short interest in December. As of December 31st, there was short interest totalling 4,540,000 shares, a decrease of 17.5% from the December 15th total of 5,500,000 shares. Based on an average daily trading volume, of 1,310,000 shares, the days-to-cover ratio is currently 3.5 days.

Analysts Set New Price Targets

A number of research firms have weighed in on ZNTL. Guggenheim cut their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Zentalis Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ZNTL. Barclays PLC increased its stake in Zentalis Pharmaceuticals by 18.5% in the 3rd quarter. Barclays PLC now owns 75,395 shares of the company’s stock worth $277,000 after buying an additional 11,748 shares during the period. XTX Topco Ltd raised its stake in shares of Zentalis Pharmaceuticals by 8.7% during the third quarter. XTX Topco Ltd now owns 194,062 shares of the company’s stock valued at $714,000 after acquiring an additional 15,597 shares in the last quarter. Quarry LP purchased a new stake in shares of Zentalis Pharmaceuticals in the third quarter valued at approximately $55,000. Paloma Partners Management Co bought a new position in Zentalis Pharmaceuticals in the third quarter worth approximately $37,000. Finally, Erste Asset Management GmbH bought a new stake in Zentalis Pharmaceuticals during the 3rd quarter valued at $37,000.

Zentalis Pharmaceuticals Trading Down 16.1 %

Shares of NASDAQ:ZNTL opened at $2.39 on Friday. The company has a market cap of $170.31 million, a price-to-earnings ratio of -0.96 and a beta of 1.86. Zentalis Pharmaceuticals has a 12 month low of $2.34 and a 12 month high of $18.07. The company has a 50-day moving average price of $3.27 and a 200 day moving average price of $3.41.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.36. As a group, equities analysts forecast that Zentalis Pharmaceuticals will post -2.48 EPS for the current year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.